Drug Profile
Research programme: phosphodiesterase 4 inhibitors - Tetra Therapeutics
Alternative Names: PDE4 inhibitors - Tetra Therapeutics; PDE4 modulators - Tetra Therapeutics; PDE4B inhibitor; PDE4D inhibitor; Phosphodiesterase 4 modulators - Tetra TherapeuticsLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Tetra Discovery Partners
- Developer Tetra Therapeutics
- Class Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease; Brain injuries; Schizophrenia
Highest Development Phases
- No development reported Brain injuries; Cognition disorders; Depressive disorders; Huntington's disease; Mild cognitive impairment; Schizophrenia
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cognition-disorders in USA
- 05 Aug 2019 Tetra Discovery Partners is now called Tetra Therapeutics
- 28 Jul 2018 No recent reports of development identified for research development in Brain injuries in USA